Clinical Trial Update: A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

A Phase II clinical trial is evaluating the combination of azacitidine and pembrolizumab for patients with relapsed or refractory Hodgkin lymphoma and is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Hodgkin's Lymphoma | Phase 2 | Status: RECRUITING